Aveanna Healthcare Holdings Inc. (AVAH)
Valuation Overview•Is Aveanna Healthcare Holdings Inc. Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
Moderate quality score of 52/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant solvency concerns.
Wall Street is highly bullish, projecting significant upside. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
AVAH demonstrates adequate business quality with stable profitability. However, this is severely offset by a highly leveraged balance sheet (Debt/EBITDA > 4.0x) and elevated financial risk.
The company demonstrates solid revenue growth (10.8% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 11.5%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $647.9M | +20.2% | +10.8% | +10.2% | — | |
| EBITDA | $83.6M | — | — | — | — | |
| Net Income | $41.7M | +2159.1% | — | — | — | |
| EPS (Diluted) | $0.19 | +1951.9% | — | — | — | |
| Free Cash Flow | -$208K | +336.2% | — | +2.5% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 32.7% | 32.0% | 31.8% | 31.4% |
| Operating Margin | 11.5% | 6.1% | -4.0% | -1.8% |
| Net Margin | 10.4% | 0.5% | -8.5% | -6.9% |
| FCF Margin | 5.4% | 2.3% | 0.4% | 0.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.13 | $0.18 | +38.5% | ||
| Q1'26 | $0.15 | $0.17 | +10.5% | ||
| Q4'25 | $0.08 | $0.15 | +87.5% | ||
| Q3'25 | $0.04 | $0.18 | +350.0% | ||
| Q2'25 | $0.03 | $0.10 | +216.8% | ||
| Q1'25 | $0.00 | $0.05 | +1178.8% | ||
| Q4'24 | $0.01 | $0.02 | +254.0% | ||
| Q3'24 | $0.00 | $0.01 | +150.0% |
Total return is +62.6% (1Y), outperforming the benchmark by +37.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -3.6% | -12.9% | — |
| 1Y | +62.6% | +37.6% | — |
| 3YCAGR | +74.0% | +52.5% | — |
| 5YCAGR | -9.1% | -22.3% | — |
| 10YCAGR | -4.2% | -18.2% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Aveanna Healthcare Holdings Inc. (AVAH) valuation, health, and returns.
Aveanna Healthcare Holdings Inc. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +44.9% upside to DCF intrinsic value of $11.29)
Aveanna Healthcare Holdings Inc. has multiple valuation anchors: DCF Intrinsic Value: $11.29 | Peer Relative Fair Value: $19.58 | Wall Street Analyst Target: $10.00 (implying +28.4% upside). A convergence of these signals offers higher conviction.
Aveanna Healthcare Holdings Inc. displays fair financial health with a composite quality score of 52/100, supported by a Altman Z-Score of 0.7 (distress zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of 15.1%.
Aveanna Healthcare Holdings Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Aveanna Healthcare Holdings Inc.'s current growth trajectory is Accelerating. The company achieved +20.2% 1Y revenue growth and +1951.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +10.8%.
Wall Street consensus is Buy based on 12 analysts, beating EPS expectations in 75% of recent quarters with a 9-quarter streak. The consensus price target represents a +28.4% change from current levels.
Investment risks for Aveanna Healthcare Holdings Inc. include: -39.4% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.96x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.